Pharmacodynamic modeling of prolonged administration of etoposide

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 1-2, 1996, Pages 61-66

  Minami, Hironobu ^a,c   Ratain, Mark J ^a   Ando, Yuichi ^b   Shimokata, Kaoru ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Cancer; Etoposide; Leukopenia; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ETOPOSIDE;

ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LEUKOPENIA; MODEL; PHASE 1 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CATHETERIZATION, CENTRAL VENOUS; ETOPOSIDE; FEMALE; HUMANS; LEUKOPENIA; MALE; MODELS, BIOLOGICAL;

EID: 0029801678     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050538     Document Type: Article

References (24)

1. Allen LM (1980) Analysis of 4′-demethylepipodophyllotoxin-9-(4,6-O-ethilidene-β-D- glucopyranoside) by high-pressure liquid chromatography. J Pharm Sci 69:1440
2. Ando Y, Minami H, Sugiura S, Ando M, Nomura F, Sakai S, Saka H, Shimokata K (1996) Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer. Jpn J Cancer Res 87:200
3. Dombernowsky P, Nissen NI (1973) Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia. Acta Pathol Microbiol Scand [A] 81:715
4. Fleming RA, Miller AA, Stewart CF (1989) Etoposide:an update. Clin Pharm 8:274
5. Fleming RA, Evans WE, Arbuck SG, Stewart CF (1992) Factors affecting in vitro protein binding of etoposide in humans. J Pharm Sci 81:259
6. Hoskins PJ, Swenerton KD (1994) Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12:60
7. Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD (1990) Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 8:1613
8. Mick R, Ratain MJ (1991) Modeling interpatient pharmacodynamic variability of etoposide. J Natl Cancer Inst 83:1560
9. Miller AA, Tolley EA, Niell HB, Griffin JP, Mauer AM (1993) Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 11:1179
10. Minami H, Shimokata K, Saka H, Saito H, Ando Y, Senda K, Nomura F, Sakai S (1993) Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer. J Clin Oncol 11:1602
11. Minami H, Ando Y, Sakai S, Shimokata K (1995) Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. J Clin Oncol 13:191
12. Murphy PB, Hainsworth JD, Greco FA, Hande KR, DeVore RF, Johnson DH (1992) A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer. Cancer 69:370
13. Radice PA, Bunn PA Jr, Ihde DC (1979) Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkins lymphomas, and other malignancies. Cancer Treat Rep 63:1231
14. Ratain MJ, Schilsky RL, Choi KE, Guarnieri C, Grimmer D, Vogelzang NJ, Senekjian E, Liebner MA (1989) Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther 45:226
15. Ratain MJ, Mick R, Schilsky RL, Vogelzang NJ, Berezin F (1991) Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 9:1480
16. Roed H, Vindelov LL, Christensen IJ, Spang-Thomsen M, Hansen HH (1987) The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell lung carcinoma of the lung. Cancer Chemother Pharmacol 19:16
17. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503
18. Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH, Wrigley PFM (1989) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7:1333
19. Stewart CF, Pieper JA, Arbuck SG, Evans WE (1989) Altered protein binding of etoposide in patients with cancer. Clin Pharmacol Ther 45:49
20. Stewart CF, Arbuck SG, Fleming RA, Evans WE (1990) Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol 8:1874
21. Stewart CF, Fleming RA, Arbuck SG, Evans WE (1990) Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients. Cancer Res 50:6854
22. Stewart CF, Arbuck SG, Fleming RA, Evans WE (1991) Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin Pharmacol Ther 50:385
23. Waits TM, Johnson DH, Hainsworth JD, Hande KR, Thomas M, Greco FA (1992) Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial. J Clin Oncol 10: 292
24. Wolff SN, Grosh WW, Prater K, Hande KR (1987) In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy. Cancer Chemother Pharmacol 19:246